TNYA — Tenaya Therapeutics Share Price
Last trade - 00:00- $350.18m
- $245.54m
- 35
- 18
- 70
- 35
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.51 | ||
| Price to Tang. Book | 2.51 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -88.77% | ||
| Return on Equity | -64.83% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 0.71 | 3.83 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company’s adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.
Directors
- David Goeddel NEC (70)
- Faraz Ali CEO (48)
- Leone Patterson CFO (58)
- Joanna Auch SVP
- Kee-hong Kim SVP (56)
- Jay Vora SVP (55)
- Timothy Hoey CSO (63)
- Matthew Pollman VPR (59)
- Jennifer Drimmer GCN
- Whittemore Tingley OTH (54)
- June Lee DRC
- Karah Parschauer DRC (43)
- Eli Casdin IND (48)
- Jin-Long Chen IND (58)
- Deepak Srivastava IND (55)
- Catherine Stehman-Breen IND (58)
- Jeffrey Walsh IND (55)
- R. Sanders Williams IND (72)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 18th, 2016
- Public Since
- July 30th, 2021
- No. of Shareholders
- 45
- No. of Employees
- 140
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 78,516,142
- Address
- 171 Oyster Point Blvd., Suite 500, SOUTH SAN FRANCISCO, 94080
- Web
- https://www.tenayatherapeutics.com/
- Phone
- +1 4158652066
- Auditors
- Deloitte & Touche LLP
Latest News for TNYA
Upcoming Events for TNYA
Similar to TNYA
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 19:21 UTC, shares in Tenaya Therapeutics are trading at $4.46. This share price information is delayed by 15 minutes.
Shares in Tenaya Therapeutics last closed at $4.46 and the price had moved by +47.68% over the past 365 days. In terms of relative price strength the Tenaya Therapeutics share price has outperformed the S&P500 Index by +19.27% over the past year.
The overall consensus recommendation for Tenaya Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Tenaya Therapeutics does not currently pay a dividend.
Tenaya Therapeutics does not currently pay a dividend.
Tenaya Therapeutics does not currently pay a dividend.
To buy shares in Tenaya Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $4.46, shares in Tenaya Therapeutics had a market capitalisation of $350.18m.
Here are the trading details for Tenaya Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: TNYA
Based on an overall assessment of its quality, value and momentum Tenaya Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Tenaya Therapeutics is $19.43. That is 335.65% above the last closing price of $4.46.
Analysts covering Tenaya Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.74 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Tenaya Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +66.26%.
As of the last closing price of $4.46, shares in Tenaya Therapeutics were trading +18.08% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Tenaya Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.46.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Tenaya Therapeutics' management team is headed by:
- David Goeddel - NEC
- Faraz Ali - CEO
- Leone Patterson - CFO
- Joanna Auch - SVP
- Kee-hong Kim - SVP
- Jay Vora - SVP
- Timothy Hoey - CSO
- Matthew Pollman - VPR
- Jennifer Drimmer - GCN
- Whittemore Tingley - OTH
- June Lee - DRC
- Karah Parschauer - DRC
- Eli Casdin - IND
- Jin-Long Chen - IND
- Deepak Srivastava - IND
- Catherine Stehman-Breen - IND
- Jeffrey Walsh - IND
- R. Sanders Williams - IND